Tags : PROfound Study

AstraZeneca and MSD Report Results of Lynparza in P-III PROfound

Shots::stososohhhhththShots: The P-III PROfound study involves assessing of Lynparza vs enzalutamide or abiraterone in patients with mCRPC, progressed on prior treatment with NHA treatments (abiraterone or enzalutamide) along with tumor mutation in BRCA1/2, ATM or one of 12 other genes involved in the HRR pathway The P-III PROfound study demonstrated improvement in OS and is […]Read More